Qinglai Lu
Independent DirectorMr. Qinglai Lu is Independent Director of Indaptus Therapeutics, Inc. from April 8, 2026. Mr. Lu has several years of experience across corporate finance, banking and debt capital markets, asset management, distressed investments and private banking in the Asia-Pacific region. Mr. Lu joined Plunkett Capital in May 2019 as Managing Partner. His key responsibilities included structuring and arranging private credit and equity financing for corporates, while deploying proprietary capital and managed funds to invest alongside such transactions; leading the firm's proprietary investment in a regional multi-family office and serving on its board, participating in strategic decision-making and major initiatives, while building deep relationships with dozens of entrepreneurial families across Asia-Pacific; developing asset management and direct investment opportunities across Asia-Pacific, with a strategic focus on Japan and Singapore. Under Mr. Lu's leadership as CEO, CPI Capital Management (Singapore) received regulatory approval from the Monetary Authority of Singapore to conduct fund management business in April 2025; and spearheading investments and asset management initiatives in virtual assets and Web3, including RWA tokenization of traditional financial assets and providing asset management solutions for stablecoin issuers. Prior to joining Plunkett Capital, Mr. Lu served as Head of Financing Solutions, Private Banking Asia at Goldman Sachs (Asia) LLC from 2018 to 2019. Mr. Lu graduated from Shanghai Jiao Tong University in 1999 with a Bachelor's degree in Communications Engineering and has been a Chartered Financial Analyst charterholder since 2005.
Positions
- Company NameIndaptus Therapeutics, Inc.Stock CodeINDPPositionIndependent Director
